NeuroBo Pharmaceuticals announced the signing of an exclusive license agreement, providing MThera Pharma with the rights to NB-01 for the treatment of painful diabetic neuropathy. The agreement allows MTHERA to conduct research and clinical trials, including, but not limited to, a potential Phase 3 clinical trial in the United States and South Korea, for the future commercialization of NB-01. Financial terms of the agreement were not disclosed.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NRBO:
- NeuroBo Pharmaceuticals files to sell 17.18M shares of common stock for holders
- NeuroBo Pharmaceuticals Releases Corporate Presentation Update
- NeuroBo Pharmaceuticals doses first patient in MAD Part 2 of DA-1726 trial
- NeuroBo Pharmaceuticals to sell 4.33M shares at $3.93 in private placement
- NeuroBo Pharmaceuticals’ DA-1726 demonstrates ‘superiority in weight loss’